肝豆状核变性的治疗现状

周思敏; 郭丽萍; 蔡王锋; 周璐; 王邦茂

doi:10.3969/j.issn.1001-5256.2020.01.052

肝豆状核变性的治疗现状

DOI: 10.3969/j.issn.1001-5256.2020.01.052

天津医科大学总医院消化科

基金项目:

国家自然科学基金地区基金项目(81860109)；

详细信息

中图分类号: R575
计量
- 文章访问数: 1057
- HTML全文浏览量: 36
- PDF下载量: 285
- 被引次数: 0
出版历程
- 出版日期: 2020-01-20

Latest advances in the treatment of hepatolenticular degeneration

Department of Gastroenterology, Tianjin Medical University General Hospital, Tianjin 300052, China

Research funding:

摘要

摘要:
肝豆状核变性(HLD)是一种与铜代谢障碍有关的常染色体隐性遗传性肝病。13号染色体ATP7B基因突变导致铜离子跨膜转运出现障碍,进而导致过量的铜在肝脏、脑、角膜、肾脏、骨关节沉积(以肝脏和脑部的铜沉积为主)。早期诊断、早期治疗可以显著减少组织损害,改善患者预后。2008年美国肝病学会、2012年欧洲肝病学会分别发布了肝豆状核变性的诊治指南。在此基础上,汇总了国内外新近的研究进展,对肝豆状核变性的治疗做出了全面的综述。
- 肝豆状核变性 /
- 早期诊断 /
- 治疗学
Abstract:
Hepatolenticular degeneration(HLD) is an autosomal recessive liver disease associated with copper metabolism disorders. Mutations in the ATP7 B gene on chromosome 13 result in impaired transmembrane transport of copper ions,which in turn leads to excessive deposition of copper in the liver,brain,cornea,kidney,and bone joints(mainly in the liver and the brain). Early diagnosis and treatment can significantly reduce tissue damage and improve the prognosis of patients. American Association for the Study of Liver Diseases issued the guidelines for the diagnosis and treatment of HLD in 2008,and the European Association for the Study of the Liver released such guidelines in 2012. This article summarizes the recent research advances in China and foreign countries to give an overview of the treatment of HLD.
- hepatolenticular degeneration /
- early diagnosis /
- therapeutics

HTML全文

参考文献(59)

[1] ROBERTS EA,SCHILSKY ML,American Association for Study of Liver Diseases(AASLD). Diagnosis and treatment of Wilson disease:An update[J]. Hepatology,2008,47(6):2089-2111.

[2] European Association for Study of Liver. EASL clinical practice guidelines:Wilson’s disease[J]. J Hepatol,2012,56(3):671-685.

[3] KOZIC'DB,PETROVIC'I,SVETEL M,et al. Reversible lesions in the brain parenchyma in Wilson’s disease confirmed by magnetic resonance imaging:Earlier administration of chelating therapy can reduce the damage to the brain[J]. Neural Regen Res,2014,9(21):1912-1916.

[4] TROCELLO JM,EL BALKHI S,WOIMANT F,et al. Relative exchangeable copper:A promising tool for family screening in Wilson disease[J]. Mov Disord,2014,29(4):558-562.

[5] SCHAEFER M,GOTTHARDT DN,DIDION C,et al. Increased prevalence of subcutaneous lipomas in patients with Wilson disease[J]. J Clin Gastroenterol,2015,49(7):e61-e63.

[6] RUSSELL K,GILLANDERS LK,ORR DW,et al. Dietary copper restriction in Wilson’s disease[J]. Eur J Clin Nutr,2018,72(3):326-331.

[7] HEDERA P. Treatment of Wilson’s disease motor complications with deep brain stimulation[J]. Ann N Y Acad Sci,2014,1315:16-23.

[8] LITWIN T,DZIEZ·YC K,KARLIN'SKI M,et al. Early neurological worsening in patients with Wilson’s disease[J]. J Neurol Sci,2015,355(1-2):162-167.

[9] POUJOIS A,MIKOL J,WOIMANT F. Wilson disease:Brain pathology[J]. Handb Clin Neurol,2017,142:77-89.

[10] SEESSLE J,GOTTHARDT DN,SCHFER M,et al. Concomitant immune-related events in Wilson disease:Implications for monitoring chelator therapy[J]. J Inherit Metab Dis,2016,39(1):125-130.

[11] SINI M,SORBELLO O,SANNA F,et al. Histologic evolution and long-term outcome of Wilson’s disease:Results of a single-center experience[J]. Eur J Gastroenterol Hepatol,2013,25(1):111-117.

[12] CHEN DB,FENG L,LIN XP,et al. Penicillamine increases free copper and enhances oxidative stress in the brain of toxic milk mice[J]. PLo S One,2012,7(5):e37709.

[13] VIEIRA BARBOSA J,FRAGA M,SALDARRIAGA J,et al. Hepatic manifestations of Wilson’s disease:12-year experience in a Swiss tertiary referral centre[J]. Swiss Med Wkly,2018,148:w14699.

[14] ALA A,ALIU E,SCHILSKY ML. Prospective pilot study of a single daily dosage of trientine for the treatment of Wilson disease[J]. Dig Dis Sci,2015,60(5):1433-1439.

[15] BREWER GJ,ASKARI F,LORINCZ MT,et al. Treatment of Wilson disease with ammonium tetrathiomolybdate:IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease[J]. Arch Neurol,2006,63(4):521-527.

[16] VADASZ Z,KESSLER O,AKIRI G,et al. Abnormal deposition of collagen around hepatocytes in Wilson’s disease is associated with hepatocyte specific expression of lysyl oxidase and lysyl oxidase like protein-2[J]. J Hepatol,2005,43(3):499-507.

[17] WEISS KH,THURIK F,GOTTHARDT DN,et al. Efficacy and safety of oral chelators in treatment of patients with Wilson disease[J]. Clin Gastroenterol Hepatol,2013,11(8):1028-1035. e1-e2.

[18] WEISS KH,STREMMEL W. Clinical considerations for an effective medical therapy in Wilson’s disease[J]. Ann N Y Acad Sci,2014,1315:81-85.

[19] RUPP C,STREMMEL W,WEISS KH. Novel perspectives on Wilson disease treatment[J]. Handb Clin Neurol,2017,142:225-230.

[20] WEISS KH,ASKARI FK,CZLONKOWSKA A,et al. Bis-choline tetrathiomolybdate in patients with Wilson’s disease:An open-label,multicentre,phase 2 study[J]. Lancet Gastroenterol Hepatol,2017,2(12):869-876.

[21] DALVI A,PADMANABAN M. Wilson’s disease:Etiology,diagnosis,and treatment[J]. Dis Mon,2014,60(9):450-459.

[22] RANUCCI G,SOCHA P,IORIO R. Wilson disease:What is still unclear in pediatric patients?[J]. Clin Res Hepatol Gastroenterol,2014,38(3):268-272.

[23] WEISS KH,GOTTHARDT DN,KLEMM D,et al. Zinc monotherapy is not as effective as chelating agents in treatment of Wilson disease[J]. Gastroenterology,2011,140(4):1189-1198. e1.

[24] CZONKOWSKA A,LITWIN T,KARLIN'SKI M,et al. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease[J]. Eur J Neurol,2014,21(4):599-606.

[25] ABUDUXIKUER K,WANG JS. Zinc mono-therapy in presymptomatic Chinese children with Wilson disease:A single center,retrospective study[J]. PLo S One,2014,9(1):e86168.

[26] EDA K,MIZUOCHI T,IWAMA I,et al. Zinc monotherapy for young children with presymptomatic Wilson disease:A multicenter study in Japan[J]. J Gastroenterol Hepatol,2018,33(1):264-269.

[27] ASKARI FK,GREENSON J,DICK RD,et al. Treatment of Wilson’s disease with zinc. XVIII. Initial treatment of the hepatic decompensation presentation with trientine and zinc[J]. J Lab Clin Med,2003,142(6):385-390.

[28] HOOGENRAAD TU. Paradigm shift in treatment of Wilson’s disease:Zinc therapy now treatment of choice[J]. Brain Dev,2006,28(3):141-146.

[29] POUJOIS A,DEVEDJIAN JC,MOREAU C,et al. Bioavailable trace metals in neurological diseases[J]. Curr Treat Options Neurol,2016,18(10):46.

[30] TEODORO T,NEUTEL D,LOBO P,et al. Recovery after copper-deficiency myeloneuropathy in Wilson’s disease[J]. J Neurol,2013,260(7):1917-1918.

[31] CHEN JC,CHUANG CH,WANG JD,et al. Combination therapy using chelating agent and zinc for Wilson’s disease[J].J Med Biol Eng,2015,35(6):697-708.

[32] ANNU A,MOHIT B. Importance of adequate decoppering in Wilson’s disease[J]. Mov Disord,2014,29(8):1089.

[33] FOX AN,SCHILSKY M. Once daily trientine for maintenance therapy of Wilson disease[J]. Am J Gastroenterol,2008,103(2):494-495.

[34] BRUHA R,MARECEK Z,POSPISILOVA L,et al. Long-term follow-up of Wilson disease:Natural history,treatment,mutations analysis and phenotypic correlation[J]. Liver Int,2011,31(1):83-91.

[35] YONETANI L,WALSHE JM. Surviving Wilson’s disease[J].Clin Med(Lond),2001,1(1):72-74.

[36] EL-KARAKSY H,FAHMY M,EL-RAZIKY MS,et al. A clinical study of Wilson’s disease:The experience of a single Egyptian Paediatric Hepatology Unit[J]. Arab J Gastroenterol,2011,12(3):125-130.

[37] ARNON R,ANNUNZIATO R,SCHILSKY M,et al. Liver transplantation for children with Wilson disease:Comparison of outcomes between children and adults[J]. Clin Transplant,2011,25(1):e52-e60.

[38] EISENBACH C,SIEG O,STREMMEL W,et al. Diagnostic criteria for acute liver failure due to Wilson disease[J]. World J Gastroenterol,2007,13(11):1711-1714.

[39] SCHILSKY ML. Liver transplantation for Wilson’s disease[J].Ann N Y Acad Sci,2014,1315:45-49.

[40] YAGCI MA,TARDU A,KARAGUL S,et al. Influence of liver transplantation on neuropsychiatric manifestations of Wilson disease[J]. Transplant Proc,2015,47(5):1469-1473.

[41] LAURENCIN C,BRUNET AS,DUMORTIER J,et al. Liver transplantation in Wilson’s disease with neurological impairment:Evaluation in 4 patients[J]. Eur Neurol,2017,77(1-2):5-15.

[42] SUTCLIFFE RP,MAGUIRE DD,MUIESAN P,et al. Liver transplantation for Wilson’s disease:Long-term results and quality-of-life assessment[J]. Transplantation,2003,75(7):1003-1006.

[43] BURKHEAD JL,GRAY LW,LUTSENKO S. Systems biology approach to Wilson’s disease[J]. Biometals,2011,24(3):455-466.

[44] MURILLO O,LUQUI DM,GAZQUEZ C,et al. Long-term metabolic correction of Wilson’s disease in a murine model by gene therapy[J]. J Hepatol,2016,64(2):419-426.

[45] ROYBAL JL,ENDO M,RADU A,et al. Early gestational gene transfer with targeted ATP7B expression in the liver improves phenotype in a murine model of Wilson’s disease[J]. Gene Ther,2012,19(11):1085-1094.

[46] HAMILTON JP,KOGANTI L,MUCHENDITSI A,et al. Activation of liver X receptor/retinoid X receptor pathway ameliorates liver disease in Atp7B(-/-)(Wilson disease)mice[J].Hepatology,2016,63(6):1828-1841.

[47] CONCILLI M,IACOBACCI S,CHESI G,et al. A systems biology approach reveals new endoplasmic reticulum-associated targets for the correction of the ATP7B mutant causing Wilson disease[J]. Metallomics,2016,8(9):920-930.

[48] FILIPPI C,DHAWAN A. Current status of human hepatocyte transplantation and its potential for Wilson’s disease[J]. Ann N Y Acad Sci,2014,1315:50-55.

[49] GUPTA S. Cell therapy to remove excess copper in Wilson’s disease[J]. Ann N Y Acad Sci,2014,1315:70-80.

[50] MALHI H,IRANI AN,VOLENBERG I,et al. Early cell transplantation in LEC rats modeling Wilson’s disease eliminates hepatic copper with reversal of liver disease[J]. Gastroenterology,2002,122(2):438-447.

[51] RODO M,CZONKOWSKA A,PULAWSKA M,et al. The level of serum lipids,vitamin E and low density lipoprotein oxidation in Wilson’s disease patients[J]. Eur J Neurol,2000,7(5):491-494.

[52] von HERBAY A,de GROOT H,HEGI U,et al. Low vitamin E content in plasma of patients with alcoholic liver disease,hemochromatosis and Wilson’s disease[J]. J Hepatol,1994,20(1):41-46.

[53] SOKOL RJ,MCKIM JM Jr,DEVEREAUX MW. alpha-tocopherol ameliorates oxidant injury in isolated copper-overloaded rat hepatocytes[J]. Pediatr Res,1996,39(2):259-263.

[54] van DEN BERGHE PV,STAPELBROEK JM,KRIEGER E,et al.Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones4-phenylbutyrate and curcumin[J]. Hepatology,2009,50(6):1783-1795.

[55] TIAN Y,GONG GZ,YANG X,et al. Diagnosis and management of fulminant Wilson’s disease:A single center’s experience[J]. World J Pediatr,2016,12(2):209-214.

[56] CHIU A,TSOI NS,FAN ST. Use of the molecular adsorbents recirculating system as a treatment for acute decompensated Wilson disease[J]. Liver Transpl,2008,14(10):1512-1516.

[57] DU YL,WU Z. Hepatolenticular degeneration involving thalamus and brainstem:A case report[J]. Clin J Med Offic,2019,47(2):220.(in Chinese)杜育霖，吴哲．肝豆状核变性累及丘脑与脑干1例[J]．临床军医杂志，2019,47(2):220.

[58] ZHANG DF,WANG YS,TENG JF. Clinical research about liver function of hepatolenticular degeneration combined liver fibrosis by transplantation of bone marrow stem cells[J]. Chin J Immunol,2016,32(2):193-196,200.(in Chinese)张东锋，王煜姝，滕军放．骨髓间充质干细胞对肝豆状核变性合并肝纤维化肝功能的临床研究[J]．中国免疫学杂志，2016,32(2):193-196,200.

[59] GOYAL MK,SINHA S,PATIL SA,et al. Do cytokines have any role in Wilson’s disease?[J]. Clin Exp Immunol,2008,154(1):74-79.

施引文献

资源附件(0)

访问统计